The CarePath platform from I-O Urology, Elizabethton, Tenn, is now available for clinical use. Under development since 2015, the CarePath system is the first and only portable product to provide real-time, quantitative measurement of uroflow and urine output. The platform, which qualifies for remote patient monitoring reimbursement, offers a patient experience that increases engagement, improves compliance, and standardizes treatment pathways for lower urinary tract symptoms (LUTS).

Today, more than 58 million Americans suffer from LUTS, such as overactive bladder and benign prostatic hypertrophy. Impractical, imprecise, and ineffective urine monitoring methods leave many patients dissatisfied with their current treatment and noncompliant with treatment protocols. The cost-effective and easy-to-use CarePath platform monitors, measures, and records serial voids in real time. Healthcare providers now have access to a standardized tool for navigating care pathways and reducing attrition for LUTS therapies.

The CarePath platform was invented by two physicians who wanted to transform the standard of care for managing LUTS by improving the quality of objective symptom reporting data and significantly reducing the patient burden inherent in traditional handwritten voiding diaries and bulky commode hats. The CarePath system features capacitive sensors and accelerometers to ensure proper orientation, as well as the latest advances in IoMT (Internet of Medical Things), radio-frequency identification, and cellular CAT M1 technology to capture, encrypt, and store objective data in the cloud. The system syncs with a mobile application that enables healthcare providers to engage with patients directly and access real-time voiding data to detect and track urologic disorders accurately. Over the past year, the technology has been available through a growing list of early access collaborations with leading healthcare providers.

“Medical therapy usually provides a small amount of symptom relief but cycling through multiple medications only potentiates the problem,” says Melissa Kaufman, MD, professor of urology, Vanderbilt Department of Urology. “With a tool like CarePath, I am able to evaluate the effectiveness of therapies much faster to determine the optimal treatment plan for each patient.”

For more information, visit I-O Urology.